Concluded Case

UPDATE ON BENEFICIAL ROLE OF ACEIS/ARBS IN HOSPITALIZED COVID19 & HTN.

Dear my friends and fellow Colleagues, Here is an update on ACEIs/ARBs in Hospitalized COVID 19 patients suffering from HTNhave a favourable outcomes on Mortality Rates. Hospitalised COVID-19 patients with Hypertension & on treatment with RAAS blockers (ACEI/ARBs) have significantly better survival (63 to 71% less mortality) compared to Hypertensive patients who are not on these drugs. A study of 1128 patients from 9 Chinese hospitals. Circulation Research, April, 2020. ESC on 17th March had given a statement to continue ACEIs/ARBs in patients suffering from HTN which is beneficial in Patients suffering from COVID 19. ESC European Society of Cardiology. AHA/ACC/HFSA on the same day ie 17th of March posted a joint statement online regarding usage of ACEIs/ARBs in COVID19. It further mentioned that urgent studies are required in this regard with regards to usage of ACEIs/ARBs in COVID 19 have either Positive or Negative effects. AHA American Heart Association ACC American College of Cardiology HFSA Heart Failure Society of America. But finally it's proven that ACEIs/ARBs have a very beneficial role in hospitalized COVID 19 patients on ACEIs/ARBs. Regards and thanks, Dr Sepuri Krishna Mohan.

3 Likes

LikeAnswersShare
Concluded answer
Wonderful update as usual Dr Mohan. But theoretically it seems that ACEIs/ARBs have a deleterious effects as they act on ACE 2Inhibitors. There was a controversy in this matter in the month of March on 17th between ESC Vs HFSA/ACC/AHA as usual. But ESC on 17th March recommend the usage of ACEIs/ARBs in Hospitalised patients with COVID-19 and HTN. As usual a very interesting and useful information Dr Mohan.
All Answers
Wonderful update as usual Dr Mohan. But theoretically it seems that ACEIs/ARBs have a deleterious effects as they act on ACE 2Inhibitors. There was a controversy in this matter in the month of March on 17th between ESC Vs HFSA/ACC/AHA as usual. But ESC on 17th March recommend the usage of ACEIs/ARBs in Hospitalised patients with COVID-19 and HTN. As usual a very interesting and useful information Dr Mohan.
Valuable opinion
0
@Dr Sandeep Debasish Mishra, Please go through this update as you had some queries regarding this aspect. I made it very clear that ESC recommended the Usage of ACEIs/ARBs in Patients suffering from HTN in COVID19. Regards and thanks, Dr Sepuri Krishna Mohan.
Informative sir
Thank you doctor
0
Dramatic turn around from earlier stand on ACEI/ ARB use in COVID 19 infection times. Earlier, even replacing ARBs by other antihyprtensives was contemplated . Then caution took over and recommendation was not to stop ACEI in normal non COVID patients . Now this update suggests that patients on ACEI / ARBs fare better when they have COVID infection and are in ICU . Dynamic changes of thought due to experience. We salute these clinical scientists who keep us updated .Thanks Dr Mohan .
Valuable opinion
0

Cases that would interest you